CA2179288A1 - Analogues de vitamines d3 et voie induisant des troubles - Google Patents

Analogues de vitamines d3 et voie induisant des troubles

Info

Publication number
CA2179288A1
CA2179288A1 CA002179288A CA2179288A CA2179288A1 CA 2179288 A1 CA2179288 A1 CA 2179288A1 CA 002179288 A CA002179288 A CA 002179288A CA 2179288 A CA2179288 A CA 2179288A CA 2179288 A1 CA2179288 A1 CA 2179288A1
Authority
CA
Canada
Prior art keywords
vitamin
analog
alpha
analogues
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002179288A
Other languages
English (en)
Inventor
Anthony W. Norman
William H. Okamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2179288A1 publication Critical patent/CA2179288A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Procédés de régulation de réponses cellulaires génomiques et non génomiques induites par 1.alpha.,25-(OH)¿2? vitamine D¿3?[1.alpha.,25-(OH)¿2?D¿3?]. Le procédé consiste à traiter des cellules présentant des réponses non génomiques à 1.alpha.,25-(OH)¿2?D¿3? à l'aide des analogues de vitamine D¿3? 1,25(OH)¿2?-provitamine D¿3? ou 1.beta.,25-(OH)¿2? vitamine D¿3? [1.beta.,25-OH)¿2?D¿3?]. La 1,25(OH)¿2?-provitamine D¿3? fait office d'agoniste stimulant la réponse cellulaire tandis que la 1.beta.,25-(OH)¿2?D¿3? fait office d'antagoniste. La transcaltachia est une des réponses non génomique affectée et pouvant être régulée par administration de 1,25(OH)¿2?-provitamine D¿3? ou 1.beta.,25-(OH)¿2?D¿3?. L'invention concerne également quinze autres analogues que l'on peut utiliser pour réguler des réponses cellulaires génomiques et/ou non génomiques.
CA002179288A 1993-12-23 1994-12-23 Analogues de vitamines d3 et voie induisant des troubles Abandoned CA2179288A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17356193A 1993-12-23 1993-12-23
US24938594A 1994-05-25 1994-05-25
US08/249,385 1994-05-25
US08/173,561 1994-05-25

Publications (1)

Publication Number Publication Date
CA2179288A1 true CA2179288A1 (fr) 1995-06-29

Family

ID=26869286

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002179288A Abandoned CA2179288A1 (fr) 1993-12-23 1994-12-23 Analogues de vitamines d3 et voie induisant des troubles

Country Status (5)

Country Link
EP (1) EP0737070A4 (fr)
JP (1) JPH09507079A (fr)
AU (1) AU1445295A (fr)
CA (1) CA2179288A1 (fr)
WO (1) WO1995017197A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA26481A1 (fr) * 1997-04-21 2004-12-20 Hoffmann La Roche Derives d'arylsecocholadiene
WO1998051663A2 (fr) * 1997-05-16 1998-11-19 F. Hoffmann-La Roche Ag Composes 3-epi de vitamine d3 et leurs utilisations
EP1891944A1 (fr) 2006-07-24 2008-02-27 Association pour la recherche à l'IGBMC (ARI) Utilisation d'une agoniste de Vitamin D3 dans une modele mammifere pour la maladie atopique et utlisation d'une antagoniste de Vitamin D3 dans le traitement de la maladie atopique
EP4081221A1 (fr) * 2019-08-22 2022-11-02 Industrial Technologies & Biotechnologies Hormone d (vitamine d) et ses dérivés pour le traitement et la prévention du cancer
CN111830157B (zh) * 2020-07-17 2022-02-25 大连美创药业有限公司 一种合成艾地骨化醇中间体的气相色谱检测方法
CN115850142A (zh) * 2022-11-25 2023-03-28 甘肃皓天医药科技有限责任公司 一种7z维生素d类化合物的合成方法

Also Published As

Publication number Publication date
WO1995017197A1 (fr) 1995-06-29
EP0737070A4 (fr) 1999-03-17
EP0737070A1 (fr) 1996-10-16
JPH09507079A (ja) 1997-07-15
AU1445295A (en) 1995-07-10

Similar Documents

Publication Publication Date Title
RU2126384C1 (ru) Аналоги витамина д, способ их получения, промежуточное соединение, фармацевтическая композиция, способ подавления болезненных состояний
Minghetti et al. 1, 25 (OH) 2‐vitamin D3 receptors: gene regulation and genetic circuitry
CN100438877C (zh) (20S)－1α－羟基－2α－甲基和2β－甲基－19－去甲－维生素D3及它们的用途
Mather et al. The growth of mouse melanoma cells in hormone-supplemented, serum-free medium
Norman et al. Structure-function studies on analogues of 1α, 25-dihydroxyvitamin D3: differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption
Norman et al. Structure-function studies of 1, 25-dihydroxyvitamin D3 and the vitamin D endocrine system. 1, 25-dihydroxy-pentadeuterio-previtamin D3 (as a 6-s-cis analog) stimulates nongenomic but not genomic biological responses
AU2005309805B2 (en) 17,20(Z)-dehydro vitamin D analogs and their uses
Simonian et al. Characterization of cultured bovine adrenocortical cells and derived clonal lines: regulation of steroidogenesis and culture life span
Qaw et al. In vivo metabolism of the vitamin D analog, dihydrotachysterol. Evidence for formation of 1 alpha, 25-and 1 beta, 25-dihydroxy-dihydrotachysterol metabolites and studies of their biological activity.
JP6383365B2 (ja) （２２Ｅ）−２−メチレン−２２−デヒドロ−１α，２４，２５−トリヒドロキシ−１９−ノル−ビタミンＤ３類似体
DE68904235T2 (de) Vitamin d-derivate : anwendung in der therapie und zur quantitativen bestimmung der vitamin d-metaboliten.
US6121469A (en) Therapeutically effective 1α,25-dihydroxyvitamin D3 analogs
Cancela et al. 1α, 25 (OH) 2 vitamin D3: A steroid hormone capable of producing pleiotropic receptor-mediated biological responses by both genomic and nongenomic mechanisms
KR100399661B1 (ko) 비타민d및아마이드유도체
Okamura et al. Studies on vitamin D and its analogs. VIII. 3-deoxy-1α, 25-dihydroxyvitamin D3, a potent new analog of 1α, 25-(OH) 2-D3
CA2179288A1 (fr) Analogues de vitamines d3 et voie induisant des troubles
Maynard et al. 14-epi stereoisomers of 25-hydroxy-and 1. Alpha., 25-dihydroxyvitamin d3: Synthesis, isomerization to previtamins, and biological studies
Posner et al. 2, 2-Disubstituted analogues of the natural hormone 1α, 25-dihydroxyvitamin D3: chemistry and biology
AU2009268557B2 (en) 2-methylene-19,26-dinor-(20R,22E,25R)-vitamin D analogs
Siu-Caldera et al. 1α, 25-dihydroxy-24-oxo-16-ene vitamin D3, a metabolite of a synthetic vitamin D3 analog, 1α, 25-dihydroxy-16-ene vitamin D3, is equipotent to its parent in modulating growth and differentiation of human leukemic cells
MXPA06000063A (es) (20s)-1alfa-hydroxi-2-metilen-19-nor-vitamina d3 y sus usos.
Napoli et al. Synthesis and biological activity of 24-hydroxy-25-fluorovitamin D3. A highly potent mediator of calcium metabolism.
Anderson et al. Stable isotope studies on steroid metabolism and kinetics: sulfates of 3α-hydroxy-5α-pregnane derivatives in human pregnancy
CA2334347C (fr) Analogues 24,24-fluores de 1-alpha,25-dihydroxy vitamine d3
Farrell et al. Isolation of desoxycorticosterone from adrenal venous blood of the dog; effect of hypophysectomy and ACTH.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead